PMID- 14706142
OWN - NLM
STAT- MEDLINE
DCOM- 20040430
LR  - 20180815
IS  - 1009-2137 (Print)
IS  - 1009-2137 (Linking)
VI  - 11
IP  - 6
DP  - 2003 Dec
TI  - [To inhibit ERK for enhancing chemotherapy sensitivity of drug-resistance cell 
      lines of leukemia and ovarian carcinoma].
PG  - 595-9
AB  - The aim was to study the roles of extracellular regulated protein kinases (ERK) 
      and telomerase activity in drug resistance of human leukemia and ovarian 
      carcinoma cells. Flow cytometry was used to analyze apoptosis rate. Telomere 
      repeat amplification protocol (TRAP) and bioluminescence analysis method were 
      used for detection of telomerase activity. The phosphorylated ERK(1/2) protein 
      expression was observed by Western blot method. The results showed that the 
      specific inhibitor PD98059 of ERK kinase 1 (MEK(1)) enhanced the sensitivity of 
      HL-60/E6 leukemia cell lines to harringtonine (HRT) or COC1/DDP ovarian carcinoma 
      cell lines to cis-dichlorodiamine platinum (DDP). Both PD98059 and chemotherapy 
      drugs HRT and DDP reduced the phosphorylated ERK(1) and ERK(2) protein expression 
      level, and down-regulated the telomerase activity. The sole action of each was 
      inferior to the combination action of PD98059 and HRT or DDP. In conclusion, ERK 
      and telomerase serve a function to some extent in drug resistance of leukemia and 
      ovarian carcinoma cells. The inhibition of ERK signal transduction pathways led 
      to reduction of phosphorylated ERK(1) and ERK(2) protein expression level, and 
      successionally down-regulated the telomerase activity. The final result was to 
      enhance the sensitivity of HL-60/E6 to HRT or COC1/DDP to DDP.
FAU - Li, Deng-Ju
AU  - Li DJ
AD  - Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan 430030, China.
FAU - Zhang, Yao-Zhen
AU  - Zhang YZ
FAU - Huang, Wei
AU  - Huang W
FAU - Meng, Fan-Kai
AU  - Meng FK
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhongguo Shi Yan Xue Ye Xue Za Zhi
JT  - Zhongguo shi yan xue ye xue za zhi
JID - 101084424
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Flavonoids)
RN  - EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
RN  - EC 2.7.7.49 (Telomerase)
RN  - SJE1IO5E3I (2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one)
SB  - IM
MH  - Apoptosis/drug effects
MH  - Drug Resistance, Neoplasm
MH  - Enzyme Inhibitors/*pharmacology
MH  - Female
MH  - Flavonoids/*pharmacology
MH  - HL-60 Cells
MH  - Humans
MH  - Leukemia/*drug therapy/pathology
MH  - Mitogen-Activated Protein Kinases/analysis/*antagonists & inhibitors
MH  - Ovarian Neoplasms/*drug therapy/pathology
MH  - Telomerase/metabolism
EDAT- 2004/01/07 05:00
MHDA- 2004/05/01 05:00
CRDT- 2004/01/07 05:00
PHST- 2004/01/07 05:00 [pubmed]
PHST- 2004/05/01 05:00 [medline]
PHST- 2004/01/07 05:00 [entrez]
AID - 1009-2137(2003)06-0595-05 [pii]
PST - ppublish
SO  - Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2003 Dec;11(6):595-9.